Omar Zgheib

Dr. Omar Zgheib


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2007 in Yeast
Verified
Journal Article
Open access
PDF file
MGM. Grenon
M. Grenon
TCThomas Costelloe
Thomas Costelloe
SJSonia Jimeno
Sonia Jimeno
AOAisling O'Shaughnessy
Aisling O'Shaughnessy
JFJennifer FitzGerald
Jennifer FitzGerald
NLNoel F. Lowndes
Noel F. Lowndes
An integrated cellular response to DNA damage is essential for the maintenance of genome integrity. Recently, post‐translational modifications to histone proteins have been implicated in DNA damage responses involving the Rad9 family of checkpoint proteins. In budding yeast, methylation of histone H3 on lysine 79 (H3‐K79me) has been shown to be required for efficient checkpoint signalling and Rad9 localization on chromatin. Here, we have used a rad9 Tudor mutant allele and cells mutated for Dot1, the H3‐K79 methylase, to analyse the epistatic relationship between RAD9 and DOT1 genes regarding the DNA damage resistance and checkpoint activation pathways. Our results show that RAD9 is epistatic to DOT1 and suggest that it acts downstream of the Dot1 methylase in the damage resistance and checkpoint response. We have also found that the Tudor domain of Rad9 is necessary for in vitro binding to H3‐K79me as well as Rad9 focal accumulation in response to DNA damage in vivo. In summary, our study demonstrates that the interaction between Rad9, via its Tudor domain, and methylated H3‐K79 is required at two different steps of the DNA damage response, an early step corresponding to checkpoint activation, and a late step corresponding to DNA repair. The study further shows that the function of this interaction is cell cycle‐regulated; the role in checkpoint activation is restricted to the G1 phase and its role in DNA repair is restricted to G2. Copyright © 2007 John Wiley & Sons, Ltd.

25 February 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
OZOmar Zgheib
Omar Zgheib
VTVéronique Trombert
Véronique Trombert
PJPeter Jandus
Peter Jandus
CSChristine Serratrice
Christine Serratrice
Mesalazine is often used as first-line therapy for ulcerative colitis. Several reports have pointed to systemic adverse reactions associated with this drug. Most have evoked a drug-induced hypersensitivity syndrome, while some have described lupus syndromes but with limited clinical and varied biological features. A 75-year-old man presented with fever, dyspnoea, chest pain, polyarthralgia, and myalgia, following mesalazine introduction. Clinical symptoms and low-titre positive antihistone antibodies disappeared after mesalazine withdrawal without recourse to steroids. Pericardial effusion and 8F-fluorodeoxyglucose uptake on positron emission tomography/CT scan, and glomerular haematuria and proteinuria also disappeared. Cytokine-lymphocyte transformation tests showed a strong sensitisation pattern with interleukin-5 production. This case advances our knowledge of the mechanism of mesalazine-induced adverse effects, namely via drug-induced hypersensitivity with lupus manifestations, which we are the first to report.

7 March 2024 in Pediatric Discovery
Verified
Journal Article
Open access
OZOmar Zgheib
Omar Zgheib
LQLina Quteineh
Lina Quteineh
PPPaloma Parvex
Paloma Parvex
CMCaterina Marconi
Caterina Marconi
VSValerie Schwitzgebel
Valerie Schwitzgebel
MBMassimiliano Bertacchi
Massimiliano Bertacchi
Nephrocalcinosis is a complex disease with a multitude of triggering factors. An association with congenital hypothyroidism has been described in the literature, but the mechanisms leading to its development remain unclear. A 7‐month‐old infant presented with muscular hypotonia and signs of malnutrition was diagnosed with congenital hypothyroidism, nephrocalcinosis of unclear origin, and multiple kidney stones. Urine analysis revealed the presence of calcium oxalate crystals and slightly elevated oxaluria without hypercalciuria. Targeted exome sequencing found no variants in the four causative genes of primary oxaluria, namely AGXT, CBX5, GRHPR, and HOGA1. The clinical outcome was favorable with thyroid hormone and potassium citrate treatment. Ultrasound follow‐up showed progressive improvement of nephrocalcinosis. The low level of urinary oxalate and the prevalence of dihydrate calcium oxalate crystals spoke against primary or secondary oxaluria. Recent evidence from mitochondrial research shows that thyroid hormone T3 enhances mitochondrial calcium levels by stimulating calcium uptake by the mitochondrial calcium uniporter. A reduced calcium uptake and metabolism in mitochondria might represent an explanation for cytoplasmic calcium accumulation in tubular cells, subsequently precipitating nephrocalcinosis in the absence of thyroid hormone. Even if the pathophysiological mechanisms are not yet fully understood, recent evidence is supportive of a causal relationship between hypothyroidism and nephrocalcinosis, a sometimes overlooked association.

1 January 2023 in Child Neurology Open
Verified
Journal Article
Open access
OZOmar Zgheib
Omar Zgheib
ATAndrea Trombetti
Andrea Trombetti
AJAndré Juillerat
André Juillerat
SFSiv Fokstuen
Siv Fokstuen
Genetic evaluation of a teenager with seizure found no pathogenic variant in a large gene panel, but an incidental likely pathogenic HNF4A variant, deemed to cause MODY1 diabetes. Diabetes history was absent and glycated hemoglobin normal, but serum calcium was severely low, with abnormally high parathyroid hormone. Thus, pseudohypoparathyroidism was suspected and confirmed by molecular genetic testing. Calcium and calcitriol supplementation led to calcium normalization and neurological symptom improvement. Given the absence of personal or family diabetes history, the HNF4A variant was reassessed and found to encode an alternative transcript with poor expression and activity levels, hence downgraded on expert advice from ‘likely pathogenic’ to ‘likely benign’. Besides illustrating the importance of structured medical workup before launching extensive targeted exome sequencing, this case highlights the need for caution in incidental finding interpretation in patients lacking compatible phenotype or family history, and the value of expert advice in such variant interpretation.

2 May 2024 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
APAriane Paoloni-Giacobino
Ariane Paoloni-Giacobino
JBJean-Louis Blouin
Jean-Louis Blouin
TNThierry Nouspikel
Thierry Nouspikel
OZOmar Zgheib
Omar Zgheib
Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance, most commonly known to affect the skin and eyes. Although lung involvement in the form of cysts and bullae occurs in up to 20% of adults, the seemingly intuitive association of NF1 and spontaneous pneumothorax is not widely recognised among clinicians. Here, we report the second case of recurring spontaneous pneumothorax in the context of NF1 with a confirmed molecular diagnosis. In both cases, the NF1 variants featured a premature stop codon in the C-terminal protein domain. Interestingly, our patient had mild skin symptoms, suggesting that spontaneous pneumothorax may not be correlated with cutaneous disease severity. More genotype–phenotype correlation studies are needed for NF1 in general and for its link to spontaneous pneumothorax in particular.

9 December 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
OZOmar Zgheib
Omar Zgheib
KCKamonwan Chamchoy
Kamonwan Chamchoy
TNThierry Nouspikel
Thierry Nouspikel
JBJean-Louis Blouin
Jean-Louis Blouin
LCLaurent Cimasoni
Laurent Cimasoni
UBUsa Boonyuen
Usa Boonyuen
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common enzymopathies in humans, present in approximately half a billion people worldwide. More than 230 clinically relevant G6PD mutations of different classes have been reported to date. We hereby describe a patient with chronic hemolysis who presents a substitution of arginine by glycine at position 219 in G6PD protein. The variant was never described in an original publication or characterized on a molecular level. In the present study, we provide structural and biochemical evidence for the molecular basis of its pathogenicity. When compared to the wild-type enzyme, the Arg219Gly mutation markedly reduces the catalytic activity by 50-fold while having a negligible effect on substrate binding affinity. The mutation preserves secondary protein structure, but greatly decreases stability at higher temperatures and to trypsin digestion. Size exclusion chromatography elution profiles show monomeric and dimeric forms for the mutant, but only the latter for the wild-type form, suggesting a critical role of arginine 219 in G6PD dimer formation. Our findings have implications in the development of small molecule activators, with the goal of rescuing the phenotype observed in this and possibly other related mutants.